| Propanc Biopharma, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2014-Mar-31 | 2013-Dec-31 | ||
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | ||
| Price to Sales | |||||||||||||||||||||||||||||||||||||||||||||||||
| Forward Price to Sales MRQ | 1.16x | 1.05x | |||||||||||||||||||||||||||||||||||||||||||||||
| Price to Book | 1.80x | 1.63x | |||||||||||||||||||||||||||||||||||||||||||||||
| Price to Earnings | - | - | |||||||||||||||||||||||||||||||||||||||||||||||
| Forward Price to Earnings MRQ | - | - | |||||||||||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | .29x | .20x | 53.96x | 65.55x | 53.22x | 100.08x | 15.73x | 17.57x | 52.67x | 21.46x | 27.99x | 30.36x | 38.03x | 18.39x | 27.60x | 38.10x | 235.15x | 108.11x | 89.83x | 42.72x | 37.96x | 76.81x | 87.69x | 23.98x | 43.31x | 14.13x | 6.48x | 68.15x | 95.58x | 62.16x | 56.39x | 42.46x | 58.24x | 106.27x | 29.27x | 10.94x | 7.77x | 3.17x | 3.23x | 11.43x | 5.87x | 6.98x | 36.46x | 35.60x | 13.38x | 29,130.85x | 89.10x | ||
| Current Ratio | 1.50x | 2.24x | - | .01x | .01x | - | .06x | .05x | .01x | .03x | .02x | .01x | - | .05x | .03x | .02x | - | .01x | .01x | .02x | .02x | .01x | - | .03x | .02x | .07x | .08x | .01x | .01x | .01x | .02x | .02x | .01x | .01x | .03x | .08x | .12x | .31x | .31x | .09x | .17x | .14x | .03x | .03x | .07x | - | .01x | ||